Looking for a Reliable Dividend Payer? Consider Buying This Blue-Chip Stock
Investing in pharmaceutical stocks can be especially lucrative. But investors need to be sure that they are picking underlying companies with both exceptional drug portfolios and pipelines. That's because this translates into a stable and growing revenue base, which can power earnings higher as well.
While there is no perfect dividend stock, Johnson & Johnson (NYSE: JNJ) is about as great as they come. Let's delve into the Dividend King's fundamentals and valuation to articulate what makes the stock a buy for income investors.
Since its founding more than 130 years ago, J&J established itself as the leading pharmaceutical company in the world. Just how big is J&J? The company's $429 billion market capitalization is nearly $100 billion greater than the $333 billion market cap of the next biggest peer, Eli Lilly (NYSE: LLY).
Source Fool.com
